{"entity":{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","aka":[],"tldr":"The world's top-ranked cancer hospital, home of MSK-IMPACT sequencing, the dostarlimab rectal cancer study, and CAR-T pioneers.","summary":"Memorial Sloan Kettering Cancer Center is a New York cancer centre founded in 1884, NCI-designated as comprehensive and ranked first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, which makes it the reference point against which other cancer hospitals are measured. Its firsts include MSK-IMPACT, an FDA-authorised tumour sequencing panel that feeds OncoKB and cBioPortal, co-development of CD19 CAR-T cell therapy with Sadelain's group, the dostarlimab study in mismatch-repair-deficient rectal cancer led by Andrea Cercek, and the Paige AI digital pathology spin-out. It runs one of the largest oncology trial portfolios in the United States. The open question for a centre this large is how quickly its knowledge reaches practice elsewhere, a bottleneck OnCo tracks explicitly. Its people and trials pages are the best way into the detail.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center","links":[{"label":"Official website","url":"https://www.mskcc.org"}],"tags":[],"related":["newsweek-hospitals","break-through-cancer"],"cancers":[],"sections":[],"technologies":["cgp","car-t","digital-pathology-ai"],"targets":[],"drugs":["dostarlimab"],"companies":["paige"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["bob-li","alexander-drilon","helena-yu","jae-park","david-solit","sharon-belvin","evelyn-lauder","jimmie-holland","john-jacob-astor-iii","komal-jhaveri","shanu-modi","monica-morrow","charles-rudin","julio-garcia-aguilar","vinod-balachandran","ghassan-abou-alfa","jonathan-rosenberg","dean-bajorin","robert-motzer","michael-postow","ingo-mellinghoff","william-tap","sandra-dangelo","nai-kong-cheung","eytan-stein","gilles-salles","steven-horwitz","jason-lewis","michael-berger","valerie-rusch","deb-schrag","andrea-cercek","charles-sawyers","eileen-oreilly","howard-scher","luis-diaz","michael-morris","ross-levine","saad-usmani","selwyn-vickers","yelena-janjigian"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.764,"lng":-73.956,"institutionType":"cancer-center","website":"https://www.mskcc.org","nci":"comprehensive","newsweekOncology2026":1,"programs":["MSK-IMPACT / OncoKB","CAR-T (Sadelain)","dMMR rectal organ preservation","Paige AI","Radiopharmaceutical development"]},"route":"/institutions/mskcc/","neighbours":{"collection":[{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/"},{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","route":"/collections/newsweek-hospitals/"},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/"}],"company":[{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/"},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/"}],"technology":[{"id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/"},{"id":"rejuv-measure-epro-as-treatment","kind":"technology","name":"Asking people how they are, every week, as a treatment in its own right","route":"/technologies/rejuv-measure-epro-as-treatment/"},{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/"},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/"},{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/"},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/"},{"id":"hair-platelet-rich-plasma","kind":"technology","name":"Platelet-rich plasma for hair after cancer treatment","route":"/technologies/hair-platelet-rich-plasma/"},{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/"},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"person":[{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/"},{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","route":"/people/alfred-sloan/"},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/"},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/"},{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","route":"/people/charles-kettering/"},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/"},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/"},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/"},{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/"},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/"},{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/"},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/"},{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/"},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/"},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/"},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/"},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/"},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/"},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/"},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/"},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/"},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/"},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/"},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/"},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/"},{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","route":"/people/john-d-rockefeller-jr/"},{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","route":"/people/john-jacob-astor-iii/"},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/"},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/"},{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/"},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/"},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/"},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/"},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/"},{"id":"monica-morrow","kind":"person","name":"Monica Morrow","route":"/people/monica-morrow/"},{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","route":"/people/mortimer-zuckerman/"},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/"},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/"},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/"},{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/"},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/"},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/"},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/"},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/"},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/"},{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/"},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/"},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/"},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/"},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/"},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/"},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/"},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/"},{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/"},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/"}],"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"trial":[{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/"},{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/"},{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/"},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/"}],"idea":[{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/"},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/"},{"id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/"},{"id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/"},{"id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/"},{"id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/"},{"id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/"},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/"},{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/"},{"id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/"},{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/"},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/"},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/"},{"id":"idea-moon-pro-monitoring-standard","kind":"idea","name":"Weekly symptom check-ins with automatic alerts as standard of care on treatment","route":"/ideas/idea-moon-pro-monitoring-standard/"},{"id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/"},{"id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/"},{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/"},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/"}],"paper":[{"id":"paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015","kind":"paper","name":"A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas","route":"/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/"},{"id":"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020","kind":"paper","name":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/"},{"id":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","kind":"paper","name":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","route":"/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/"},{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/"},{"id":"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","kind":"paper","name":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","route":"/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/"},{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/"},{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/"},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/"},{"id":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","kind":"paper","name":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","route":"/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/"},{"id":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","kind":"paper","name":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","route":"/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/"},{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/"},{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/"},{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/"},{"id":"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","kind":"paper","name":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","route":"/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/"},{"id":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","kind":"paper","name":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","route":"/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/"},{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/"},{"id":"paper-park-hrd-pancreatic-platinum-ccr-2020","kind":"paper","name":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","route":"/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/"},{"id":"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018","kind":"paper","name":"Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations","route":"/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/"},{"id":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","kind":"paper","name":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","route":"/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/"},{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/"},{"id":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","kind":"paper","name":"Integrative genomic profiling of human prostate cancer","route":"/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/"},{"id":"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017","kind":"paper","name":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","route":"/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/"},{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/"},{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/"},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/"},{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/"},{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/"},{"id":"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","kind":"paper","name":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","route":"/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/"},{"id":"paper-makohon-moore-precursor-cells-ductal-system-nature-2018","kind":"paper","name":"Precancerous neoplastic cells can move through the pancreatic ductal system","route":"/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/"},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/"},{"id":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","kind":"paper","name":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","route":"/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/"},{"id":"paper-quail-joyce-microenvironment-metastasis-natmed-2013","kind":"paper","name":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis","route":"/key-papers/paper-quail-joyce-microenvironment-metastasis-natmed-2013/"},{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/"},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/"},{"id":"paper-rizvi-mutational-landscape-pd1-science-2015","kind":"paper","name":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer","route":"/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/"},{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/"},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/"},{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/"},{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/"},{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/"},{"id":"paper-schoenfeld-smarca4-alterations-lung-ccr-2020","kind":"paper","name":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","route":"/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/"},{"id":"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019","kind":"paper","name":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","route":"/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/"},{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/"}],"roadmap":[{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/"},{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"institution":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/"},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/"},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/"},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/"},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/"},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/"},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"}],"pathway":[{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/"},{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/"},{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/"},{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/"},{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/"},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/"},{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/"},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/"},{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/"},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/"},{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/"},{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/"},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/"},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/"},{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1-NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/"},{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/"},{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/"},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/"},{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/"},{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/"},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/"}]}}